Screener
Amphastar Pharmaceuticals AMPH Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
FAQ
- What is Amphastar Pharmaceuticals's cash & equivalents?
- Amphastar Pharmaceuticals (AMPH) reported cash & equivalents of $223.61M in Q2 2026.
- How has Amphastar Pharmaceuticals's cash & equivalents changed year-over-year?
- Amphastar Pharmaceuticals's cash & equivalents increased by 19.1% year-over-year, from $187.69M to $223.61M.
- What is the long-term trend for Amphastar Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's cash & equivalents has grown at a 12.9% compound annual growth rate (CAGR), from $92.64M to $170.18M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Amphastar Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude